ENTA

7.6204.51%
ST

Scott T. Rottinghaus

Chief Medical Officer

Dr. Scott T. Rottinghaus, M.D., is Chief Medical Officer of Enanta Pharmaceuticals, Inc. from August 08, 2022 and served as its Senior Vice President from August 08, 2022. He joined Enanta from Alexion, AstraZeneca Rare Disease, He was in clinical development at Alexion, a global biopharmaceutical company, since 2015. He served as Vice President and Head of Clinical Development for Hematology and Nephrology since March 2019 until August 2022. He is an infectious disease trained physician who has experience in drug development across a broad range of therapeutic areas. Dr. Rottinghaus was in clinical development at Pfizer Inc., a global pharmaceutical company, from 2007 to 2015, most recently as Senior Director and a Global Clinical Lead. He served as an Assistant Clinical Professor of Medicine since 2017 until 2019 and a Clinical Instructor of Medicine from 2008 to 2017 at Yale School of Medicine. Dr. Rottinghaus received a Doctorate in Medicine from Mayo Medical School after earning an M.Sc. (Biology) from University of Cambridge and a B.A. (Classics) in Latin and Greek and B.S. (Biology) from Kansas State University.

Positions